West Pharmaceutical Services/$WST

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About West Pharmaceutical Services

West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Ticker

$WST
Sector

Primary listing

NYSE

Employees

10,600

WST Metrics

BasicAdvanced
$19B
40.10
$6.68
1.05
$0.84
0.31%

What the Analysts think about WST

Analyst ratings (Buy, Hold, Sell) for West Pharmaceutical Services stock.

Bulls say / Bears say

Q2 2025 net sales rose 9.2% year-over-year to $766.5 million and adjusted diluted EPS reached $1.84, resulting in gross margin expansion to 35.7% and operating margin at 20.1% (Investing.com).
Management raised full-year 2025 guidance to $3.04–$3.06 billion in net sales (up from $2.945–$2.975 billion) and $6.65–$6.85 adjusted EPS (from $6.15–$6.35), signaling confidence in ongoing robust demand (Investing.com).
GLP-1 elastomer products contributed 8% of total revenue and high-value product components grew by 11.3%. KeyBanc reaffirmed its Overweight rating on West due to its near-total participation in injectable GLP-1 capacity expansion projects (Investing.com).
Contract-manufacturing segment grew just 3.0% year-over-year to $146.7 million in Q2 2025, highlighting slower growth outside the company’s higher-margin proprietary products segment (Investing.com).
In Q1 2025, organic net sales increased only 2.1% while adjusted diluted EPS declined to $1.45 from $1.56 a year earlier, emphasizing uneven demand momentum and margin pressure resulting from restructuring and lower-value product mix (Investing.com).
West continues to expect $20–25 million in tariff-related costs and remains vulnerable to currency fluctuations, factors that could pressure margins in the future despite recent foreign-exchange benefits (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.

WST Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

WST Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $WST

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

FAQs